Biogen’s stock tumbles after the U.S. proposes restricting access to its Alzheimer’s disease drug

Regulators have proposed limiting access to the class of Alzheimer's disease drugs that includes the company's therapy, Aduhelm.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.